Filter posts

FDA Check-Up: Drug Development and Manufacturing Challenges

I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current …

Approving Drugs for Alzheimer’s Disease

BIOtechNOW delves into the current state of Alzheimer’s disease research with today’s feature on regulatory …

A Bright Future for Orphan Disease Indications

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved …

Celgene CEO on New Multiple Myeloma Drug Approvals

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one …

FDASIA: A Step Forward for Patients

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act …

"When Genetic Engineering Came Of Age"

October 29 was the 30th anniversary of the approval by the Food and Drug Administration …

BIO Investor Forum - Raring to Go: The Race to Treat Ultra-Rare Diseases

The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering …

Indices, IPOs, Approvals - YTD Update Aug 14th, 2012

We are now more than eight months into the year and biotech indices have maintained their outperformance, squeezed …

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the …

Indices, IPOs, and New Drug Approvals - Update April 3rd 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its …